17 March 2015
BVD Webinars Provide Effective CPD Opportunity for Busy Cattle Vets
MILTON KEYNES, UK, March 17, 2015 - Cattle vets will have the opportunity to update their knowledge on Bovine Viral Diarrhoea (BVD) by taking part in two interactive webinars with disease expert Dr Richard Booth BVSc PhD BSc (Hons) MRCVS in April. These will cover the following topics:
- 15th April - Helping your clients take action on BVD
- 22nd April - BVD diagnostics and control – a tailored approach
Dr Booth, a cattle vet who is currently lecturing in infectious cattle diseases at the Royal Veterinary College London, has been involved since 2006 with an extensive research project on what is one of the most widespread and potentially devastating infectious diseases for UK cattle herds. Through his work, he has become one of the leading authorities on all aspects of BVD, including its transmission, the impact on farms, diagnostics and methods of control and eradication.
The 45 minute interactive online sessions take place from 8.15pm and are free by registering at www.msd-animal-health-cpd.co.uk. All vets registering will also receive a free recording of their webinar.
The webinar programme is being provided by MSD Animal Health, manufacturer of BOVILIS® BVD, which has been proven for over 15 years in the field and is the UK’s most widely recommended BVD vaccine1.
Use medicines responsibly. For more information visit: www.noah.co.uk/responsible
BOVILIS® BVD is an inactivated vaccine containing 50 ELISA units (EU) and inducing at least 4.6 log2 VN units per dose of cytopathogenic BVD virus strain C86. Legal category: POM-V. BOVILIS BVD is only available from your veterinary surgeon from whom advice should be sought. BOVILIS BVD is the property of Intervet International B.V. or affiliated companies or licensors and are protected by copyrights, trademark and other intellectual property laws. Copyright © 2014 Intervet International B.V. All rights reserved.
For information regarding side effects, precautions, warnings and contra-indications please refer to the datasheet at www.noahcompendium.co.uk. Further information is available from MSD Animal Health, Walton Manor, Walton, Milton Keynes, MK7 7AJ. Tel: 01908 685 685 • firstname.lastname@example.org • www.msd-animal-health.co.uk
1 – GfK data MAT February 2015
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to theScience of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no
guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).